Brought to you by 
Becton Dickinson acquires PharMingen for cash
13 Jul 1999
Executive Summary
In an effort to expand its flow cytometry business, Becton Dickinson has acquired PharMingen (biomedical research products) for cash. BD's existing flow cytometry business, comprised of both instruments and reagents, generates about $200mm.
Deal Industry
- In Vitro Diagnostics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Becton Dickinson acquires PharMingen for cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice